Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option
Targeting the cell cycle could overcome cancer treatment resistance
3 March 2022US traffic deaths rise to highest level since 2007
3 March 2022Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option
Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with disease progression, were published today in Nature Medicine.
